 A phase 3 clinical trial evaluating bardoxolone methyl for the treatment of chronic kidney disease (CKD) was terminated in October 2012 after patients treated with the drug were found to have experienced a higher rate of heart-related adverse events, including heart failure, hospitalizations, and deaths.Investigations of bardoxolone methyl have been conducted by Reata Pharmaceuticals in a partnership with Abbvie and Kyowa Hakko Kirin.A Phase 1 clinical trial, sponsored by Reata, was conducted to determine the safety profile of and appropriate dosing for subsequent phase II studies, as well as to evaluate antitumor activity in patients with advanced solid
tumor or lymphoid malignancy.